Efficacy of once-daily glucagon-like peptide-1 receptor agonist lixisenatide as an add-on treatment to basal insulin in Asian and white adults with type 2 diabetes mellitus: An individual-level pooled analysis of phase III studies.

Liu F, Liu Y, Liu M, Wu G, Zhang M, Zhang X, Cui N, Yin H, Chen L

Journal of diabetes investigation28 Feb 2021Cited by 3 (Europe PMC)

PMID33475222PMCIDPMC8354505DOI10.1111/jdi.13504PepBankPUB-33475222

Read at source PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study8

8 results from studies that gave the peptide. 8 results from people.

01HumanNon-randomized trialEfficacy outcome
In Asian patients with diabetes on basal insulin, lixisenatide reduced HbA1c versus placebo, with a least squares mean difference of -0.49.
In plain wordsIn Asian patients with diabetes on basal insulin, lixisenatide reduced HbA1c versus placebo.
Peptide
Lixisenatide
Outcome
DecreaseHbA1c treatment effect in Asian patients
Study
n: not reported in source
Comparator
Placebo
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated
Measurements
HbA1c difference
−0.49 not stated
Asian patients
Confidence interval
−0.68 to −0.3 not stated
95% confidence interval
Source sentences
Summary
After 24 weeks, lixisenatide reduced HbA1c in both ethnic groups, with no statistically significant difference between the two groups (Asian patients least squares mean difference -0.49, 95% confidence interval -0.68 to - 0.30 and white patients least squares mean difference -0.45, 95% confidence in…
1 context sentence(design, population, supporting numbers)
Summary · context
An individual-level pooled analysis of two multi-national phase III studies, GetGoal-L and GetGoal-L-C, was carried out to assess the efficacy of lixisenatide versus placebo as an add-on treatment to BI ± metformin in Asian and white patients with type 2 diabetes mellitus.
Report a problemFND-3347522201
02HumanNon-randomized trialEfficacy outcome
In white patients with diabetes on basal insulin, lixisenatide reduced HbA1c versus placebo, with a least squares mean difference of -0.45.
In plain wordsIn white patients with diabetes on basal insulin, lixisenatide reduced HbA1c versus placebo.
Peptide
Lixisenatide
Outcome
DecreaseHbA1c treatment effect in white patients
Study
n: not reported in source
Comparator
Placebo
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated
Measurements
HbA1c difference
−0.45 not stated
white patients
Confidence interval
−0.63 to −0.26 not stated
95% confidence interval
Source sentences
Summary
After 24 weeks, lixisenatide reduced HbA1c in both ethnic groups, with no statistically significant difference between the two groups (Asian patients least squares mean difference -0.49, 95% confidence interval -0.68 to - 0.30 and white patients least squares mean difference -0.45, 95% confidence in…
1 context sentence(design, population, supporting numbers)
Summary · context
An individual-level pooled analysis of two multi-national phase III studies, GetGoal-L and GetGoal-L-C, was carried out to assess the efficacy of lixisenatide versus placebo as an add-on treatment to BI ± metformin in Asian and white patients with type 2 diabetes mellitus.
Report a problemFND-3347522202
03HumanNon-randomized trialEfficacy outcome
In Asian patients with diabetes, lixisenatide contributed to an adjusted HbA1c reduction of -0.56%.
In plain wordsIn Asian patients with diabetes, lixisenatide contributed to lower HbA1c after adjustment for starting HbA1c.
Peptide
Lixisenatide
Outcome
DecreaseAdjusted HbA1c reduction in Asian patients
Study
n: not reported in source
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated
Measurements
Adjusted HbA1c reduction
−0.56%
Asian patients
Source sentences
Summary
Treatment with lixisenatide contributed to HbA1c reduction of -0.56% after adjustment of baseline HbA1c level in Asian patients, and -0.41% in white patients.
1 context sentence(design, population, supporting numbers)
Summary · context
An individual-level pooled analysis of two multi-national phase III studies, GetGoal-L and GetGoal-L-C, was carried out to assess the efficacy of lixisenatide versus placebo as an add-on treatment to BI ± metformin in Asian and white patients with type 2 diabetes mellitus.
Report a problemFND-3347522205
04HumanNon-randomized trialEfficacy outcome
In white patients with diabetes, lixisenatide contributed to an adjusted HbA1c reduction of -0.41%.
In plain wordsIn white patients with diabetes, lixisenatide contributed to lower HbA1c after adjustment for starting HbA1c.
Peptide
Lixisenatide
Outcome
DecreaseAdjusted HbA1c reduction in white patients
Study
n: not reported in source
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated
Measurements
Adjusted HbA1c reduction
−0.41%
white patients
Source sentences
Summary
Treatment with lixisenatide contributed to HbA1c reduction of -0.56% after adjustment of baseline HbA1c level in Asian patients, and -0.41% in white patients.
1 context sentence(design, population, supporting numbers)
Summary · context
An individual-level pooled analysis of two multi-national phase III studies, GetGoal-L and GetGoal-L-C, was carried out to assess the efficacy of lixisenatide versus placebo as an add-on treatment to BI ± metformin in Asian and white patients with type 2 diabetes mellitus.
Report a problemFND-3347522206
05HumanNon-randomized trialEfficacy outcome
In Asian patients with diabetes on basal insulin, lixisenatide reduced 2-hour postprandial glucose versus placebo, with a least squares mean difference of -3.37.
In plain wordsIn Asian patients with diabetes on basal insulin, lixisenatide reduced glucose two hours after meals versus placebo.
Peptide
Lixisenatide
Outcome
DecreaseTwo-hour postprandial glucose reduction in Asian patients
Study
n: not reported in source
Comparator
Placebo
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated
Measurements
2-h PPG LS mean difference
−3.37 not stated
Asian patients
Source sentences
Summary
Similarly, no significant difference was found in 2-h PPG reduction between both groups (least squares mean difference for Asian vs white patients: -3.37 vs -3.93; P = 0.3203).
1 context sentence(design, population, supporting numbers)
Summary · context
An individual-level pooled analysis of two multi-national phase III studies, GetGoal-L and GetGoal-L-C, was carried out to assess the efficacy of lixisenatide versus placebo as an add-on treatment to BI ± metformin in Asian and white patients with type 2 diabetes mellitus.
Report a problemFND-3347522207
06HumanNon-randomized trialEfficacy outcome
In white patients with diabetes on basal insulin, lixisenatide reduced 2-hour postprandial glucose versus placebo, with a least squares mean difference of -3.93.
In plain wordsIn white patients with diabetes on basal insulin, lixisenatide reduced glucose two hours after meals versus placebo.
Peptide
Lixisenatide
Outcome
DecreaseTwo-hour postprandial glucose reduction in white patients
Study
n: not reported in source
Comparator
Placebo
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated
Measurements
2-h PPG LS mean difference
−3.93 not stated
white patients
Source sentences
Summary
Similarly, no significant difference was found in 2-h PPG reduction between both groups (least squares mean difference for Asian vs white patients: -3.37 vs -3.93; P = 0.3203).
1 context sentence(design, population, supporting numbers)
Summary · context
An individual-level pooled analysis of two multi-national phase III studies, GetGoal-L and GetGoal-L-C, was carried out to assess the efficacy of lixisenatide versus placebo as an add-on treatment to BI ± metformin in Asian and white patients with type 2 diabetes mellitus.
Report a problemFND-3347522208
07HumanObservational studyEfficacy outcome
In patients with diabetes, HbA1c treatment effects of lixisenatide did not differ significantly between Asian and white patients (P = 0.6287).
In plain wordsIn patients with diabetes, the HbA1c response to lixisenatide was similar between Asian and white patients.
Peptide
Lixisenatide
Outcome
No significant changeHbA1c treatment response by ethnicity
Study
n: not reported in source
Comparator
White patients
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated
Measurements
HbA1c LS mean difference
−0.49 not stated
Asian patients
HbA1c LS mean difference
−0.45 not stated
white patients
P value
0.6287 not stated
ethnicity comparison
Source sentences
Summary
After 24 weeks, lixisenatide reduced HbA1c in both ethnic groups, with no statistically significant difference between the two groups (Asian patients least squares mean difference -0.49, 95% confidence interval -0.68 to - 0.30 and white patients least squares mean difference -0.45, 95% confidence in…
1 context sentence(design, population, supporting numbers)
Summary · context
An individual-level pooled analysis of two multi-national phase III studies, GetGoal-L and GetGoal-L-C, was carried out to assess the efficacy of lixisenatide versus placebo as an add-on treatment to BI ± metformin in Asian and white patients with type 2 diabetes mellitus.
Report a problemFND-3347522203
08HumanObservational studyEfficacy outcome
In patients with diabetes, postprandial glucose reductions with lixisenatide did not differ significantly between Asian and white patients (-3.37 versus -3.93).
In plain wordsIn patients with diabetes, glucose reductions after meals with lixisenatide were similar between Asian and white patients.
Peptide
Lixisenatide
Outcome
No significant changePostprandial glucose treatment response by ethnicity
Study
n: not reported in source
Comparator
White patients
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated
Measurements
2-h PPG LS mean difference
−3.37 not stated
Asian patients
2-h PPG LS mean difference
−3.93 not stated
white patients
P value
0.3203 NA
ethnicity comparison
Source sentences
Summary
Similarly, no significant difference was found in 2-h PPG reduction between both groups (least squares mean difference for Asian vs white patients: -3.37 vs -3.93; P = 0.3203).
1 context sentence(design, population, supporting numbers)
Summary · context
An individual-level pooled analysis of two multi-national phase III studies, GetGoal-L and GetGoal-L-C, was carried out to assess the efficacy of lixisenatide versus placebo as an add-on treatment to BI ± metformin in Asian and white patients with type 2 diabetes mellitus.
Report a problemFND-3347522204

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
28 Oct 2026, 02:03 UTC
Study results updated
Version 1
27 Oct 2026, 16:36 UTC
First added · source update from Europe PMC

PepBank is a research reference. Talk to a doctor before you use any peptide.

Efficacy of once-daily glucagon-like peptide-1 receptor agonist lixisenatide as an add-on treatment to basal insulin in Asian and white adults with type 2 diabetes mellitus: An individual-level pooled analysis of phase III studies.

Summary

Results from this study8

Version history

Subjects

Publication types

MeSH terms

Keywords